Journal
PHARMACEUTICALS
Volume 16, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/ph16020239
Keywords
inflammatory bowel disease; vedolizumab; treatment outcome
Categories
Ask authors/readers for more resources
This study compared the clinical outcomes of intravenous and subcutaneous vedolizumab in inflammatory bowel disease patients. They found that subcutaneous administration resulted in higher drug concentration and demonstrated comparable efficacy and safety to intravenous administration. Few patients discontinued therapy due to loss of response, and the most common adverse event was COVID-19.
Little is known about how the change from intravenous to subcutaneous vedolizumab in a real-life setting in inflammatory bowel disease patients on stable maintenance therapy affects clinical outcomes. We compared the data on vedolizumab serum trough concentration, efficacy, and safety prior to and six months after the switch from intravenous to subcutaneous vedolizumab. In total, 24 patients, 13 with ulcerative colitis (UC) and 11 with Crohn's disease (CD), were included. Mean serum trough concentration of intravenous vedolizumab was significantly lower than mean serum trough concentration of subcutaneous vedolizumab (p = 0.002). There was no significant difference between C-reactive protein levels, fecal calprotectin levels or clinical scores (Harvey-Bradshaw index or Partial Mayo score) prior to transition to subcutaneous vedolizumab and after 6 months. In four (16.7%) patients, two CD and two UC, therapy was discontinued during the follow-up period with a median of 5 months (minimum-maximum: 4-6). In all patients, therapy was discontinued due to loss of response. In total, 13 adverse events were reported by 11 patients, and the most common adverse event was COVID-19. No serious adverse events were reported. In conclusion, subcutaneous vedolizumab has shown to be effective and safe in patients on previously established maintenance therapy with intravenous vedolizumab.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available